ERYTECH Pharma S.A. ERYP
Set alert
As of Jun 28, 3:48 PM ET
52-week range unavailable
- Open
- 0.8195
- Prev close
- 0.78
- Mkt cap
- 47.40M
- Vol
- 3.21K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.78
- High
- 0.84
- Forward P/E
- -0.28
- Beta
- 2.13
- Short ratio
- 1.10
- Inst. own
- 7.65%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Apr 26, 2023
- 50-d avg
- 0.859266
- 200-d avg
- 0.743274
- 1y target
- 2.96
Key statistics
- Market cap
- 47.40M
- Enterprise value
- -719.32K
- Trailing P/E
- 0.00
- Forward P/E
- -0.28
- PEG ratio
- 0.00
- Price / sales
- 7.13
- Price / book
- 1.03
- EPS (TTM)
- -0.01
- Beta
- 2.13
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -3.43%
- Revenue (TTM)
- 6.65M
- Revenue growth
- 571.50%
- Free cash flow
- -21.08M
- Total cash
- 38.79M
- Total debt
- 13.57M
- Return on equity
- -0.98%
- Shares outstanding
- 60.75M
- Short % of float
- 0.00%
- 50-day average
- 0.859266
- 200-day average
- 0.743274
Analyst view
Consensus: hold
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Apr 26, 2023
Expected Apr 26, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Apr 26, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Mar 9, 2021 | Dec 1, 2020 | -1.00 | — | — | — |
| Mar 18, 2020 | Dec 1, 2019 | -0.86 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2017 | Cowen & Co. | init | — | Outperform |
About ERYTECH Pharma S.A.
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- France
- Website
- erytech.com
News
- Erytech Pharma SA (ERYP) Q1 2023 Earnings Call Transcript
- Why Is Erytech Pharma (ERYP) Stock Up 47% Today?
- ERYTECH Pharma S.A. (ERYP) Q3 2022 Earnings Call Transcript
- Why Cango Shares Are Trading Higher; Here Are 27 Stocks Moving Premarket
- Why Laser Photonics Shares Jumped By Around 44%; Here Are 72 Biggest Movers From Yesterday
- Erytech Pharma SA Sponsored ADR (ERYP) Upgraded to Buy: Here's Why
- Stocks That Hit 52-Week Lows On Tuesday
- Stocks That Hit 52-Week Lows On Thursday
- Stocks That Hit 52-Week Lows On Monday
- Stocks That Hit 52-Week Lows On Tuesday
Your note
Sign in to keep a note on ERYP — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0.73% | 248,426 | 193.77K | Mar 30, 2023 |
| Millennium Management Llc | 0.09% | 30,802 | 24.02K | Mar 30, 2023 |
| Vanguard Personalized Indexing Management, LLC | 0.07% | 24,271 | 18.93K | Mar 30, 2023 |
| Mariner, LLC | 0.07% | 23,904 | 18.64K | Mar 30, 2023 |
| Virtu Financial LLC | 0.06% | 20,026 | 15.62K | Mar 30, 2023 |
| Citadel Advisors Llc | 0.03% | 10,807 | 8.43K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.01% | 2,542 | 1.98K | Feb 27, 2023 |